Radiotheranostics: a roadmap for future development

Ken Herrmann, Markus Schwaiger, Jason S Lewis, Stephen B Solomon, Barbara J McNeil, Michael Baumann, Sanjiv S Gambhir, Hedvig Hricak, Ralph Weissleder

Radiotheranostics, injectable radiopharmaceuticals with antitumour effects, have seen rapid development over the past decade. Although some formulations are already approved for human use, more radiopharmaceuticals will enter clinical practice in the next 5 years, potentially introducing new therapeutic choices for patients. Despite these advances, several challenges remain, including logistics, supply chain, regulatory issues, and education and training. By highlighting active developments in the field, this Review aims to alert practitioners to the value of radiotheranostics and to outline a roadmap for future development. Multidisciplinary approaches in clinical trial design and therapeutic administration will become essential to the continued progress of this evolving therapeutic approach.

Introduction

Theranostics is an emerging and expanding medical field based on therapeutic interventions after imaging to verify the presence of a biological target. Although the combination of imaging and therapy dates back 70 years,1 the field has progressed rapidly over the past decade. In 2018 alone more than 1000 publications were published on the topic according to a PubMed search for theranostic advances in diverse fields, including radioisotope-based therapeutics (radiotheranostics); bioimage-guided radiotherapy delivery;2,3 optical imaging, laser ablations, and surgery (optotheranostics);4,5 nanotherapeutics;6 interventional oncology;7 and basic sciences.

Radiotheranostics is perhaps the most clinically advanced application of theranostics, with many developments and emerging opportunities. A key aspect of radiotheranostics is that the selection of patients for radiotargeted treatments is based on imaging of the same target area; therefore, imaging and therapeutic intervention are closely linked. The concept of radiotheranostics has been around for more than 70 years, prime examples include using different forms of radioactive iodine to diagnose (eg, ¹²⁴I) and treat (eg, ¹³¹I) thyroid cancers.8,9 With radioactive iodine, metastatic thyroid cancer was transformed from a disease with poor outcome to a disease with about 85% overall survival.8 Nowadays, radiotheranostics is at a point of change, and is moving into the mainstream of cancer therapeutics. The main goals of radiotheranostatic indications have been to stabilise end-stage disease that is refractive to other treatments and to improve quality of life in these patient populations. Early clinical trials have improved outcomes for patients with otherwise untreatable prostate and thyroid cancers,10 as well as neuroendocrine tumours. Future objectives include treating early-stage cancer through targeted intervention and reducing the side-effects of systemic radiotherapy. Several radiopharmaceuticals that aim to meet these objectives are in development for cancer treatment (table 1). Radiotheranostics are also being explored for non-cancer applications, such as ⁹⁰Y-silicate joint injections (radiation synovectomy) for severe arthritis.11 A number of new radioisotopes are expected to further improve the therapeutic window and efficacy (mainly for cancer), and image-guided interventional strategies are poised to deliver therapeutics locally with high precision. US Food and Drug Administration (FDA) approval of ¹⁷⁷Lu-dotatate (Lutathera, Adacap [Novartis]) in neuroendocrine tumours, and the potential of a soon to be approved theranostic (¹⁷⁷Lu-PSMA-617, Adacap [Novartis]) for patients with prostate cancer, is likely to shift radiotheranostics into the mainstream of cancer care. Market analysts predict considerable revenue growth (figure 1) and pharmaceutical companies are now investing in radiotheranostics.12–15

Despite the promising possibilities, the field also faces obstacles. This Review discusses key questions from the viewpoint of translational leaders in radiotheranostics and the broader membership of the International Society of Strategic Studies in Radiology. We seek to alert practitioners to the value of radiotheranostics and to outline a roadmap for future development.

Background

The status of clinical radiotheranostics trials

The ligand-linker-radioisotope design is the general structure used in radiotheranostics (figure 2).16 The targeting ligand serves as an anchor and acts to locally enrich the therapeutic radioisotope in or near the cancer. The targeting ligand is commonly a peptide (eg, octreotide, acetate targeting somatostatin receptor type 2 [SS2R]), small molecule (eg, fibroblast-activated protein inhibitor [FAP]I), or antibody (eg, against CD20, CD37, or CA 19-9). These radiopharmaceuticals have different macrocyclic chelates (DOTA [1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid] and others) that trap α (²²³Ra or ²²⁵Ac) and β emitters (¹⁷⁷Lu, ⁹⁰Y, or ¹⁶⁶Ho).17 Similar chemical constructs are used concomitantly for diagnostic PET, single-photon-emission (SPECT)-CT, and MRI, and largely rely on γ or positron emitters (⁹⁹mTc, ⁶⁸Ga, ¹⁸F, or ⁶⁸Cu). Planar and SPECT-CT scans can also be obtained with the γ component of ¹⁷⁷Lu and ¹⁶⁶Ho. These chemical designs are for systemic administration, although exceptions to this structure include nanoparticle and microparticle therapeutics (eg, ⁹⁰Y or ⁶⁸Ho microspheres) that are usually given intra-arterially by image-guided intervention (figure 2). Other exceptions to the generic design include radioactive forms of free iodine that accumulate in thyroid cancer cells through the sodium fluoroanion pathway.

Reference

Lancet Oncol 2020; 21: e146–56

Clinic for Nuclear Medicine, University Hospital Essen, Essen, Germany (K Herrmann MD); Department of Nuclear Medicine, Klinikum Rechts der Isar, Technical University Munich, Munich, Germany (M Schwaiger MD); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York City, NY, USA (J S Lewis PhD, S B Solomon MD, H Hricak MD); Department of Radiology, Brigham and Women’s Hospital, and Department of Health Care Policy, Harvard Medical School, Boston, MA, USA (B J McNeil MD); German Cancer Research Center (DKFZ), Heidelberg, Germany (M Baumann MD); Department of Radiology and Molecular Imaging Program, Stanford University, Stanford, CA, USA (S S Gambhir MD); Department of Radiology, and Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA (R Weissleder MD)

Correspondence to: Dr Ralph Weissleder, Center for Systems Biology, Massachusetts General Hospital, Boston, MA 02114, USA ralph_weissleder@hms.harvard.edu
iodide transporter (eg, $^{124}$I for imaging and $^{131}$I for therapy) and certain radimetals (eg, $^{223}$Ra). Other reviews discuss the use of iodine in more detail and thus will not be covered here.17

Supported by the early successes of using radioiodine therapy for thyroid conditions, subsequent attempts were made to treat haematological malignancies, because these cancers typically respond well to radiotherapy. With CD20 as a target, $^{131}$I-tositumomab (Bexxar) and $^{90}$Y-ibritumomab tiuxetan ($\text{Zevalin}$) have been studied for the treatment of B-cell lymphomas,18,19 and both were subsequently US FDA approved for relapsed or refractory non-Hodgkin lymphoma (table 1). In 2014, $^{90}$Y-ibritumomab tiuxetan was used for consolidation

<table>
<thead>
<tr>
<th>Ligand</th>
<th>Therapeutic isotope</th>
<th>Imaging isotope</th>
<th>Target</th>
<th>Manufacturer</th>
<th>Disease</th>
<th>Clinical trial phase or approval date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Iodine</td>
<td>None</td>
<td>$^{131}$I $^{124}$I $^{129}$I</td>
<td>NaI symporter</td>
<td>Curium, GE Healthcare</td>
<td>Thyroid cancer</td>
<td>NA</td>
</tr>
<tr>
<td>Dotatate (Lutathera)</td>
<td>Peptide</td>
<td>$^{111}$Lu $^{64}$Ga $^{111}$In</td>
<td>SS2R</td>
<td>Adacap (Novartis)</td>
<td>Neuroendocrine tumours</td>
<td>Approved, 2018</td>
</tr>
<tr>
<td>Satoreotide tetraetan</td>
<td>Peptide</td>
<td>$^{111}$Lu $^{64}$Ga</td>
<td>SS2R</td>
<td>Ipsen</td>
<td>Neuroendocrine tumours, small-cell lung cancer, and breast cancer</td>
<td>Phase 1 and 2</td>
</tr>
<tr>
<td>PSMA-617</td>
<td>Small molecule</td>
<td>$^{111}$Lu $^{64}$Ga $^{18}$F</td>
<td>PSMA</td>
<td>Adacap (Novartis)</td>
<td>Castration-resistant prostate cancer</td>
<td>Phase 3</td>
</tr>
<tr>
<td>Lexodronam (Quadramet)</td>
<td>None</td>
<td>$^{153}$Sm $^{99}$Tc $^{18}$NaF</td>
<td>New bone formation</td>
<td>Lamheus</td>
<td>Bone metastases</td>
<td>Approved, 1997</td>
</tr>
<tr>
<td>Radium223 (Xrogo)</td>
<td>None</td>
<td>$^{223}$Ra $^{99}$Tc $^{18}$NaF</td>
<td>Calcimimetic</td>
<td>Bayer</td>
<td>Prostate cancer and bone metastases</td>
<td>Approved, 2013</td>
</tr>
<tr>
<td>Strontium89 (Metastron)</td>
<td>None</td>
<td>$^{89}$Sr $^{18}$NaF</td>
<td>New bone formation</td>
<td>GE Healthcare</td>
<td>Bone pain</td>
<td>Approved, 1993</td>
</tr>
<tr>
<td>Ibritumomab tiuxetan (Zevalin)</td>
<td>Antibody</td>
<td>$^{90}$Y</td>
<td>None</td>
<td>CD20</td>
<td>Spectrum Pharmaceuticals</td>
<td>Relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin lymphoma</td>
</tr>
<tr>
<td>Tositumomab (Bexxar)</td>
<td>Antibody</td>
<td>$^{131}$I $^{111}$I $^{124}$I</td>
<td>Noepinephrine transporter</td>
<td>Progenics</td>
<td>Pheochromocytoma and Paraganglioma</td>
<td>Approved, 2018</td>
</tr>
<tr>
<td>Iobenguane (Azedra)</td>
<td>Antibody</td>
<td>$^{111}$I $^{131}$I $^{123}$I</td>
<td>Norepinephrine transporter</td>
<td>Progenics</td>
<td>Pheochromocytoma and Paraganglioma</td>
<td>Approved, 2018</td>
</tr>
<tr>
<td>Apamistamab (Iomab-B)</td>
<td>Antibody</td>
<td>$^{131}$I</td>
<td>None</td>
<td>CD45</td>
<td>Actinium Pharmaceuticals</td>
<td>Bone marrow ablation</td>
</tr>
<tr>
<td>Lilotomab satetraetan (Beta.lt)</td>
<td>Antibody</td>
<td>$^{111}$Lu</td>
<td>None</td>
<td>CD37</td>
<td>Nordic</td>
<td>Indolent non-Hodgkin lymphoma, follicular lymphoma, diffuse large B-cell lymphoma</td>
</tr>
<tr>
<td>Omburtamab</td>
<td>Antibody</td>
<td>$^{131}$I</td>
<td>None</td>
<td>CD27/6</td>
<td>Ymabs Therapeutics</td>
<td>Neuroblastoma, CNS metastases, and small-round-cell tumour</td>
</tr>
<tr>
<td>3BP-227</td>
<td>Small molecule</td>
<td>$^{111}$Lu $^{125}$I $^{127}$I</td>
<td>NTSR1</td>
<td>Ipsen</td>
<td>Pancreatic ductal adenocarcinoma, colorectal cancer, and gastric cancer</td>
<td>Phase 1</td>
</tr>
<tr>
<td>FAPI</td>
<td>Small molecule</td>
<td>$^{90}$Y, $^{131}$I, $^{135}$I, $^{125}$I</td>
<td>$^{18}$F</td>
<td>FAP</td>
<td>Pancreatic ductal adenocarcinoma, colorectal cancer, and head and neck cancer</td>
<td>Compassionate use (Germany)</td>
</tr>
<tr>
<td>Pentixafor</td>
<td>Peptide</td>
<td>$^{111}$Lu $^{131}$I</td>
<td>$^{48}$GA</td>
<td>C-XCR-4</td>
<td>Pentixafor</td>
<td>Multiple myeloma and lymphoma</td>
</tr>
<tr>
<td>Glass microspheres</td>
<td>None</td>
<td>$^{90}$Y</td>
<td>None</td>
<td>Tumour vessels (angiogenesis)</td>
<td>Hepatocellular carcinoma</td>
<td>Approved, 2000</td>
</tr>
<tr>
<td>Resin microspheres</td>
<td>None</td>
<td>$^{90}$Y</td>
<td>None</td>
<td>Tumour vessels (angiogenesis)</td>
<td>Hepatocellular carcinoma and liver metastases</td>
<td>Approved, 1998</td>
</tr>
<tr>
<td>Microspheres</td>
<td>None</td>
<td>$^{111}$Ho</td>
<td>$^{111}$Ho</td>
<td>Tumour vessels (angiogenesis)</td>
<td>Hepatocellular carcinoma and liver metastases</td>
<td>Phase 2</td>
</tr>
</tbody>
</table>

The list shows common radiotheranotactics, but is not comprehensive. The availability and development of radiotheranotactics varies between countries. NA=not applicable. SSR2=somatostatin receptor type 2. PSMA=prostate-specific membrane antigen. NTRST1=neurotensin receptor type 1. FAP=fibroblast-activated protein inhibitor. FAP=fibroblast-activated protein inhibitor. FAP=fibroblast-activated protein inhibitor. FAP=fibroblast-activated protein inhibitor. FAP=fibroblast-activated protein inhibitor.

Table 1: Summary of radiotheranotactics for cancer treatment
therapy after frontline chemotherapy. However, despite promising clinical results, neither approved product was financially successful and did not find wide clinical traction because of complicated logistics, the absence of a trained workforce, reimbursement concerns, and, in particular, competing non-radioactive therapies, all of which impeded widespread clinical use. Lessons from these early products are still relevant nowadays and highlight the need for more interdisciplinary strategies.²⁰

In solid tumours, the first prospective randomised phase 3 trial with therapeutic radioactive radioisotopes that showed a benefit to survival was the ALSYMPCA study (²²³Ra).²¹ ²²³Ra was given to male patients with bone metastases from castration-resistant prostate cancer with no visceral metastases. The mechanism of action of ²²³Ra, which is an α emitter, is through its incorporation into areas of new bone formation. Analysis of 921 patients showed significantly improved survival for patients who received six doses of 50 Bq ²²³Ra isotope in addition to standard-of-care therapy compared with standard-of-care alone (median overall survival of 14·9 months vs 11·3 months, hazard ratio 0·70 [95%CI 0·58–0·83]). Patients treated with ²²³Ra had a low frequency of myelosuppression despite radioactive treatment and fewer adverse events than the control group, leading to its FDA approval in 2013 (table 1). ²²³Ra radiotreatment is recommended by the European Society for Medical Oncology (2015)²² and the National Comprehensive Cancer Network (2016)²³ and was also supported by most panellists in a 2018 consensus meeting.²⁴

One radiotheranostic application targeted cancers that overexpressed SSR2.²⁵ Such malignancies include neuroendocrine tumours, and, to a lesser degree, small-cell lung cancer. The therapeutic part of this approach is ¹⁷⁷Lu-dotatate, with ⁶⁸Ga-dotatate as the diagnostic counterpart. Examples of scans of patients who responded or did not respond to this regimen are in figure 3. A randomised controlled trial published in 2017 evaluated the efficacy and safety of ¹⁷⁷Lu-dotatate in patients with advanced midgut neuroendocrine tumours and showed longer progression-free survival and a significantly higher response than participants treated with high-dose octreotide acetate.²⁶ Clinically significant myelosuppression occurred in fewer than 10% of patients. ¹⁷⁷Lu-dotatate received US FDA for Molecular Oncology (EMA) approval in 2018 (table 1). Results from the same trial published in 2018 showed that clinically relevant symptoms such as diarrhoea, fatigue, and pain developed over a significantly longer time period in patients on ¹⁷⁷Lu-dotatate than high-dose octreotide acetate.²⁷ Furthermore, patients had a longer sustained function in health-related quality-of-life categories, including those pertaining to basic and advanced daily-living activities. Administration of ¹⁷⁷Lu-dotatate is done in four systemic doses, and should always be coupled with intravenous infusion of amino acids for nephroprotection. However, based on compassionate use data, renal radionephropathy was rarely observed, even after 6–8 cycles of treatment.²⁸²⁹

Alternative strategies to ¹⁷⁷Lu-dotatate include octreotide acetate derivatives linked to cytotoxins (eg, maitansine conjugate, PEN-221), which can be given for more than four doses. Finally, efforts to design SS2R antagonists, rather than agonists, are in development.

Another advanced radiotheranostic indication is the targeting of prostate-specific membrane antigen (PSMA) in prostate cancer. PSMA is expressed in 85–95% of patients with late-stage prostate cancer, and of those, 40–60% respond to ¹⁷⁷Lu-PSMA-617 (a small molecule drug containing ¹⁷⁷Lu and targeting PSMA), as evidenced by a decrease in prostate-specific antigen (PSA) of greater than 50%.³⁰³¹ For the 5–15% of patients who are PSMA-negative, as determined by imaging, PSMA-directed treatment is of no benefit. Most patients given ¹⁷⁷Lu-PSMA-617 can be treated as outpatients, and side-effects are relatively uncommon but not absent. In one recent single-arm study,¹¹ 30 patients with metastatic castration-resistant prostate cancer who had progressed after conventional standard-of-care treatments were given ¹⁷⁷Lu-PSMA-617; these patients had a high PSA response, few toxic effects, and effective pain reduction. These data led to the initiation of an ongoing randomised phase 3 trial (VISION; NCT03511664) for metastatic castration-resistant prostate cancer in thirdline postnovel androgen therapy and post-taxane therapy. Radiographic progression-free survival and overall survival will serve as primary endpoints; trial recruitment finished in the second half of 2019.

A meta-analysis published in 2018 included 455 patients in Europe and Australia, where ¹⁷⁷Lu-PSMA-617 has been
most widely applied as part of compassionate use programmes. In this analysis, PSA declined in two-thirds of patients, with a more than 50% reduction seen in a third of patients following the first cycle of $^{177}$Lu-PSMA-617. These encouraging data triggered the initiation of multiple prospective PSMA-directed multicentre trials, including both single arm (NCT03042312) and randomised controlled study designs (NCT03392428).

Another US FDA-approved radioactive therapeutic is $^{131}$I-iobenguane (MIBG; Azedra), which is aimed at patients with unresectable adrenal tumours, such as pheochromocytoma and paragangliomas. The FDA granted this application fast-track, breakthrough therapy, priority review, and orphan drug designation on the basis of a single arm, open-label clinical trial in 68 patients. The study met the primary endpoint by confirming that 25% of patients reduced hypertensive medication dose by 50% or more for at least 6 months, with an overall tumour response in 22% of patients. This treatment has been used in similar clinical indications for more than 10 years in many countries outside the USA.

Additional compounds in phase 2 and phase 3 trials in clinical development include the CD37-targeting radioligand conjugate $^{177}$Lu-DOTA-HH1 (litotriam satrastetan) for haematological malignancies and $^{131}$I-labelled omurtamab for patients with advanced neuroblastoma. The companies producing these therapies are in close discussions with the US FDA and aim for approval in the near future. Several other radiotheranostics are also in the latter stages of development (table 1).

### Patient acceptance and effect on quality of life

Systemic administration of radiotheranostics is simple procedures and well tolerated by most patients. Compared with chemotherapy or other targeted therapies, the number of reported side-effects is lower and primarily consists of fatigue and nausea. The potential short-term and long-term toxic effects depend on the ligand and the respective radioisotope, but include nephrotoxicity (<10% for $^{177}$Lu-dotatate) and myelosuppression (about 25%), and when these side-effects are present, patients might require a reduction in dose. Furthermore, long-term data will have to be gathered in larger patient populations.

In many cases, quality-of-life measurements have gained traction as qualified outcome parameters with the US FDA, EMA, and insurers. The NETTER-1 trial ($^{177}$Lu-dotatate), for example, showed significantly improved health-related quality-of-life measurements. This outcome is in line with another single-centre study focusing on SS2R-targeted radiotheranostics in midgut neuroendocrine tumours, as well as PSMA-targeted radioligand therapy in prostate cancer. Favourable outcomes on quality of life were also reported for numerous other theranostic applications in thyroid cancer and bone metastases. The ongoing VISION study ($^{177}$Lu-PSMA-617; NCT03511664) also investigates quality-of-life parameters (health-related quality of life; EQ-5D-5L; Functional Assessment of Cancer Therapy-Prostate; Brief Pain Inventory) as secondary outcomes, in addition to safety and tolerability.

### Best route of administration: systemic or image-guided?

Most radiotheranostics are given systemically (intravenously) to treat known or potentially disseminated disease to minimise invasiveness. However, in certain instances, the delivery of intravenous radiotheranostics can be challenging to deliver in sufficient doses to target tumour cells, while also trying to minimise off-target toxicity. In some patients with localised disease, these issues might be overcome with catheter-delivered intraarterial radiotheranostics.

The selectivity of theranostics in catheter-delivered radioisotopes have used lipiodol tumour affinity or simple tumour hypervascularity. Lipiodol has been labelled with both $^{131}$I and $^{188}$Rh, and microspheres with $^{90}$Y and $^{166}$Ho, for treatment. $^{90}$Y resin microspheres (SIR-Spheres) and theraspheres have been approved in several countries.
for use in primary liver cancers and metastatic disease. More recently, there has been interest in combining the superselectivity of catheter-directed therapy with biologically targeted theranostic agents such as dotatate. Initial studies have shown that intra-arterial $^{90}$Y or $^{177}$Lu-dottate can be delivered safely and decrease hepatic metastases. This intra-arterial approach has also been applied in meningiomas, which also express SSR2. For patients with meningioma receiving both intravenous and intra-arterial delivery of $^{177}$Lu-dottate, the intra-arterial option provided higher doses and was more cytotoxic with fewer systemic side-effects.

Lastly, interventional techniques such as tumour ablation can be coupled with the biologic selectivity of targeted imaging agents to create a theranostic effect. For example, PSMA PET-guided cryoablation and stereotactic radiotherapy of oligometastatic prostate cancer have recently been shown to have a synergistic effect.

Challenges

There are several challenges facing the clinical translation and more widespread use of radiotheranostics (table 2). The overall guiding principle is to provide the best possible care to large segments of cancer patients in a fiscally responsible manner. We categorise the challenges as technical, economic, or biomedical.

Technical challenges

First and foremost is the general shortage of interdisciplinary teams with standardised and efficient protocols. The use of radioactive substances is highly regulated and primarily reserved for diagnostic use in nuclear medicine and radiology. Physicians working with theranostics must bridge interdisciplinary boundaries and form disease-oriented teams, much like existing tumour boards. This approach will probably be necessary to implement adequate processes for selecting the right patients and delivering the most appropriate therapies. Establishment of such teams is already happening in centres worldwide, with a few in the USA and many more in Europe and Australia, but should now be done more widely. Second, is the occasional restricted availability of therapeutic radioisotopes and their sources, because of aging reactors, a lack of investment into new reactors, and production that does not conform with good manufacturing practices. There are also global differences in the availability of different radioisotopes and the hope is that these bottlenecks can be overcome through a coordinated industrial scale-up process.

Economic challenges

Reimbursement and clinical responsibilities coupled with use of alternative therapies often remains poorly defined and varies from country to country. Despite these hurdles, successes in neuroendocrine tumours and prostate cancer have led to investments by the pharmaceutical industry and support from the US FDA.

Adequate research funding to prove the value of theranostics, largely done through large interdisciplinary teams, will be useful in providing support for well-designed prospective clinical trials.

Biomedical challenges

These challenges include the small number of radiotheranostics on the market, as well as the absence of both large-scale prospective trials and research into combination treatments. Some of these issues are being addressed by developing new targeting ligands, radioisotopes, and applications. Basic, preclinical, and translational research are particularly important to the progress in this field, and will need to be supported appropriately by pharmaceutical companies and regulatory agencies.

Recommendations

We suggest a number of recommendations to address existing challenges (table 2).

Radiotheranostics pipeline

The development pipeline is varied and includes additional indications for existing radiotheranostic agents and new targets, radioisotopes, targeting ligands, and treatment combination therapies. Each of these approaches should be studied in more detail in future
Table 2: Challenges in developing clinical radiotheranostics: reasons and possible solutions

<table>
<thead>
<tr>
<th>Technical or organisational challenges</th>
<th>Solution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absence of interdisciplinary treatment teams</td>
<td>Create multidisciplinary disease teams</td>
</tr>
<tr>
<td>Small workforce</td>
<td>Revise training programmes, implement e-learning tools</td>
</tr>
<tr>
<td>Bottlenecks in radioisotope availability</td>
<td>Scale-up through commercial vendors</td>
</tr>
<tr>
<td>Uneven global availability</td>
<td>Scale-up through commercial vendors</td>
</tr>
<tr>
<td>Regulatory challenges</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Economic challenges</th>
<th>Solution</th>
</tr>
</thead>
<tbody>
<tr>
<td>High development cost</td>
<td>Prospective comparative multicentre trials</td>
</tr>
<tr>
<td>Reimbursement ill-defined</td>
<td>Cost–benefit analysis in low and middle-income countries</td>
</tr>
<tr>
<td>Insufficient access to funding with decreased research budgets</td>
<td></td>
</tr>
<tr>
<td>Competing technologies</td>
<td></td>
</tr>
<tr>
<td>Global differences</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Biomedical challenges</th>
<th>Solution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Few available drugs</td>
<td>Explore new nucleides to target ligands and indications</td>
</tr>
<tr>
<td>Absence of large-scale prospective trials</td>
<td>Multicentre prospective clinical trials, design and conduct clinical trials (expertise, training, and sites)</td>
</tr>
<tr>
<td>Combination treatments largely unexplored</td>
<td>Prospective clinical trials (based on preclinical evidence)</td>
</tr>
</tbody>
</table>

Clinical trials. In order to more rapidly explore novel agents, developing facilitated procedures (eg, fast track approvals, simplified regulations for clinical studies, and adequate good manufacturing practice redefinition for radiopharmaceuticals) to test new (diagnostic) radiopharmaceuticals that can be given intravenously in minute amounts might be necessary. Although regulations are different between countries, often these guidelines are so stringent that they hinder the exploration of new pharmaceuticals.

New indications

A number of different cancers, other than neuroendocrine tumours, overexpress SS2R (eg, breast, small-cell lung cancer, pheochromocytoma, and meningioma), and PSMA expression is not restricted to prostate cancer (hepato-cellular carcinoma, renal cell cancer). $^{177}$Lu-dotatate is currently being explored for the treatment of pheochromocytoma, paraganglioma, and meningioma. $^{16,19}$ $^{177}$Lu-OXS201 for breast and small-cell lung cancer (NCT03773133), and PSMA-617 for hepato-cellular carcinoma. $^{23}$

As with other new therapeutic approaches, late-stage cancers are often explored first—eg, NETTER-1$^{18}$ focused on secondline treatment, and the ongoing VISION study investigates thirdline treatment in metastatic castration-resistant prostate cancer after novel androgen axis therapy and post-taxane therapy. Future trials should investigate the option to start radiotheranostic therapy earlier. Preliminary data are encouraging for $^{177}$Lu-dotatate-like therapeutic concepts in the neoadjuvant setting $^{21}$ and for $^{177}$Lu-PSMA-617 before radical prostatectomy and pelvic lymph node dissections. $^{22}$

New targets

Ideal targets are selectively overexpressed in a tumour or tumour-associated cell, are absent or expressed at low amounts in physiological tissues, and have an extracellular component. $^{24}$ New biological targets include the C-X-C chemokine receptor type 4 (CXCR-4)–SDF-1 axis (figure 4) $^{25}$ and prolyl endopeptidase FAP, which is up-regulated by cancer-associated fibroblasts. $^{26}$ The FAPi family targets the microenvironment and has been licensed to Sofie Biosciences in 2019. First-in-human use has already been reported for both targets, and additional prospective trials are anticipated. Additional targets under clinical investigation are the gastrin-releasing peptide receptor (GRP-R) and the integrin αβ, or αβ, receptors, among others. Haematological malignancies, such as CD38 positive myeloma cells or CD45 positive acute myeloid leukaemia cells, are also attractive targets for radiotheranostics. Such therapies not only offer considerable benefits for clinical outcomes, but also positively affect quality of life, and many more targets are currently being studied. $^{37}$ Radionuclide therapy often requires only a single infusion visit compared with more frequent infusions for cold-antibody maintenance therapy. $^{20}$

New radioisotopes

To further develop theranostics, an option is to expand the range of therapeutic radioisotopes (table 1). Common therapeutic radioisotopes include $^{177}$Lu, $^{90}$Y, and $^{131}$I, which can enact their therapeutic effect via β emission. α-emitting radioisotopes, such as $^{225}$Ac, $^{213}$Bi, $^{212}$Pb, and $^{211}$At, are particularly appealing because they convey substantially more energy than β emitters and have a smaller depth of penetration in tissue (about 5 mammalian cell diameters), which increases the damage to tumour cells. Despite encouraging data for $^{225}$Ac-PSMA-617 in prostate cancer, clinical translation will probably take longer for β-emitting theranostics because of logistical challenges (eg, production of radionuclides, waste management, and half-life) and the potential for more severe toxic effects. $^{39}$ The efficacy of different radioisotopes for tumours of varied size will also be important to study in future trials.

New targeting ligands and approaches

Expanding the range of radioactively-labelled ligands beyond the use of peptides is feasible and promising; for example, the expansion of radiotheranostics as antibodies will increase the number of druggable targets. In addition, there are opportunities for development with small molecules, nanobodies, and engineered proteins. As well as developing new targeting ligands, pretargeted radioimmunotherapy could also be used to improve efficacy compared with therapies that do not use pretargeting. In this two-step approach, patients first receive non-radioactive tumour-targeting...
antibodies, and after a delay (24–48 h) to allow for blood clearance and tumour accumulation, patients receive a low-molecular weight radioactive agent with high affinity for the homed antibody. Most pretargeted radioimmunotherapy approaches in a preclinical setting have used antibody–streptavidin conjugates or fusion proteins labelled with ⁹⁰Y-DOTA biotin.²⁰ Click-chemistry approaches in preclinical studies have been developed for pretargeting in imaging and therapeutic applications.¹⁹–³²

Combination therapies
The most suitable way to improve clinical acceptance of theranostics, as well as increase clinical effectiveness, is through the identification of optimal combinations of theranostic agents with other synergistic treatments, including chemotherapy, targeted inhibitors, and immunotherapies. Despite the success of ¹⁷⁷Lu-dotatate in the NETTER-1 trial,²⁰ only 1% of patients achieved complete response. To cure patients undergoing PSMA-targeted radiotheranostics in a thirdline setting is likely to be impossible. The question is how do we best combine treatments to achieve high success rates?²¹ Since radiotheranostics stimulate the immune response, they might enhance the efficacy of immunotherapy.⁶⁴ Combinations of ¹⁷⁷Lu-dotatate with nivolumab are being tested for the treatment of small-cell lung cancer (NCT03325816) and ¹⁷⁷Lu-PSMA-617 with pembrolizumab in metastatic prostate cancer (NCT03805594). Investigations into combining radiotheranostics with conventional chemotherapy (capecitabine; NCT02736500) or targeted inhibitors for radiosensitising (olaparib; NCT03874884) are ongoing. Preclinical trials and early clinical data suggest that integrating radiotheranostics with external beam radiotherapy is a promising avenue for further translational studies.⁶⁵

Future clinical trials
As the portfolio of cancer therapeutics widens, the right choice, timing, and combination of interventions will become the main challenge of precision oncology. With respect to radiotheranostics, we envision future trials that can address the stage of disease, dosing, combination treatments, and new indications.

Targeting different stages
New therapeutics are usually first introduced as palliative regimens in advanced metastatic disease. Following phase 1 and 2 evaluations, positive results in prospective randomised trials are vital to clinical approval and reimbursement processes. In the past decade, all radiotheranostic approaches have followed this route to US FDA approval and Centers for Medicare and Medicaid Services reimbursement. However, the ultimate goal is for earlier detection and frontline radiotheranostics (eg, in prostate cancer) to be included into the pathway for approval. This concept will have to be carefully tested in well designed, step-wise, multicentre prospective clinical trials. In prostate cancer, one possible next step is to test curative PSMA theranostics as a frontline therapy. The low-toxicity profile of PSMA theranostics, mainly because of a small molecule that targets PSMA, might allow earlier application of PSMA therapy. Radiosensitivity and favourable dosimetry in localised early disease might therefore provide curative potential in prostate cancer therapy.

Expanding of dose
Most radiotheranostic therapies are restricted to a single administration (for many haematological malignancies) or a low number of administrations (for solid cancers). For example, ¹⁷⁷Lu-dotatate is limited to four doses as the tolerability has not yet been shown in prospective studies. Most pharmaceutical companies recommend that radiopharmaceuticals should be given to patients as a universal standard dose; however, pretherapeutic and post-therapeutic imaging can be used for more accurate dose-finding and for individualising the treatment of patients.⁶⁶,⁶⁷ Furthermore, because only a few dose escalation studies have been done to date (NCT03773133, NCT02592707, NCT03525392, NCT03490838), future clinical studies are warranted to explore dose escalation and timing. These efforts should similarly encompass more accurate dosimetry predictions based on quantitative imaging studies by PET/CT.
Exploring new indications

Several new indications await investigation in future prospective trials and the treatment of haematological malignancies is a logical next step, given the plethora of targets accessible to antibodies. The stepwise introduction of new indications, and combining theranostics with other regimens such as immunotherapies, requires close partnerships between the pharmaceutical industry and academic institutions. Theranostic applications beyond cancer (ie, for inflammatory disease), might also stimulate industry interest and motivate the necessary funding of clinical trials.

Training the next generation of physicians, physicists, radiochemists, and radiopharmacists

The clinical use of radiotheranostics can be more complex than use of conventional chemotherapy because of logistical challenges and regulatory hurdles. However, these difficulties can all be addressed. For example, considerations include attention to radiation safety during the application of treatment and in waste management, the limited half-life of the therapy (hours or days compared to months for chemotherapy), and the possibility and need for imaging after radiotheranostic administration. The safe application of radiotheranostics requires a specialised and well-trained team of physicians, radiochemists, medical physicists, and nurses to ensure patient safety. Clearly defined roles within a team are necessary when it comes to diagnosis, drug preparation, radiation safety, treatment, monitoring, and follow-up. Strategically aligning all training goals is crucial, particularly in view of the field’s expected expansion.

There is an international shortage in the number of trained radiochemists required to produce diagnostic and therapeutic radiopharmaceuticals (State of the Science of Nuclear Medicine, commissioned by the National Research Council of the National Academies). Formulating and safely dispensing these drugs requires additional expertise in the field of radiopharmacy. This expertise is particularly important when handling large quantities of therapeutic radioisotopes, such as β-emitting and α-emitting nuclides. Radiopharmacists also need these skills, because practicing pharmacy includes reviewing patient profiles and answering questions related to the drug and its uses. Technologists, medical physicists, and nurses would also require specialised training to care for patients receiving radiotheranostics. Medical physicists must understand both radiation safety and dosimetry. For personalised medicine to be realised in the context of radiotheranostics, board-certified medical physicists who are experts in patient dosimetry and endoradiotherapy dose-planning will be key. These personnel are in short supply and supplemental training with short internships or fellowships that specifically focus on endoradiotherapy would help support professionals in the field. Finally, e-learning approaches, exchange programmes, and medical student teaching should be considered in the future to try and expand the use of radiotheranostics to other countries.

The use of radiotheranostics in the clinical practice will depend on well trained nuclear medicine and radiology physicians who can bridge the divides between radiochemistry and pharmacy, nuclear imaging, clinical investigation, and different fields of clinical oncology. Building these bridges can be achieved by creating a nuclear medicine training programme based on cutting-edge research in tandem with a specialised training curriculum in patient management that emphasises the handling and management of targeted radioisotope therapy side-effects.

The success of theranostics will require attention to the education and training of future generations of specialists. Concepts that have been discussed include additional oncology training and fellowships for nuclear medicine or additional theranostics training for oncologists. More specifically, we suggest that following standard residency in radiology or nuclear medicine, imaging physicians should complete a 1–2-year fellowship in molecular imaging and radiotheranostics. This training should follow a minimum of 1 year in a clinical medical or oncology internship. Medical oncology fellowships should dedicate 6–12 months to allow fellows to rotate through different radiotheranostic programmes. For oncologists who currently have little experience in nuclear medicine-based radiotheranostics, this training programme would promote familiarity and confidence in these novel techniques.

For all professions involved, our communities and societies must ensure high standards are maintained via recertification, board reviews, and recredentialing, depending on the local and national requirements. These recertifications should not be burdensome; rather, they should be used to maintain the highest levels of standards and safety. Furthermore, the multidisciplinary tumour board model is a successful way to bring together all the physicians responsible for managing patients. In this model, the fellowship-trained nuclear medicine physician would work together with the radiologist, medical oncologist, radiation oncologist, surgeon, and others to manage the patient safely and to coordinate management of side-effects.
Summary
Radiotheranostics are cell-killing radiation strategies that combine molecular targeting and optimised radiation dosimetry and are likely to emerge as an important player among cancer treatments (nuclear oncology). Despite these promising qualities, radiotheranostics are still at an early stage of development. Initial clinical success will determine the extent to which specialist radiotheranostic centres and the number of trained individual specialists. Fruitful partnerships with industry will be essential to the successful growth of radiotheranostics.

Funding
SSG, JSL, SBS, MB, HH, and RW received grant support from the National Cancer Institute (NCI). JSL, SBS, and HH are supported by a P30 Cancer Center Support Grant (P30 CA008748) to The Memorial Sloan Kettering Cancer Center, an NCI-designated comprehensive cancer centre. MS acknowledges support of the Deutsche Forschungsgemeinschaft.

Declaration of interests
KH reports personal fees from Bayer, SIRETX, Adacap, Curium, Endocyte, IPSEN, Siemens Healthineers, GE Healthcare, Amgen, and Novartis; non-financial support from ABX; grants and personal fees from BTG; and stock options (<2% of the company) from Sofie Biosciences, outside the submitted work. MS reports personal fees from GE Healthcare outside the submitted work. SBS reports grants from the German Cancer Research Centre. MB reports personal fees from AbbVie, CereNext Pharma, Endra, and Great Point BV (GPBV); other support from Akroteine Imaging, Cellsights Technologies, CytomX Therapeutics, Grail, ImaginAb, MagArray, Nodus Therapeutics, Puretech, RefleXion Medical, SiteOne Therapeutics, Spectrum Dynamics, and Vor Biopharma; and personal fees and other from EARLI, Nine, Nasuno, and Vave Health, outside the submitted work. HI reports personal fees from Ion Beam Applications, outside the submitted work. RW reports personal fees from Tarveda Pharmaceuticals and ModeRNA; personal fees and non-financial support from Accure Health and Luminell; and non-financial support from T2Biosystems (Shareholder), outside the submitted work. BJM declares no competing interests.

References


72 Ahmadzadehfar H, Essler M. It is time to move forward into the era of theranostics. EJNMMI Res 2018; 8: 9.
©2020 Elsevier Ltd. All rights reserved.